Trials / Completed
CompletedNCT00408616
Efficacy and Safety of Grazax in Children
A Phase III Trial Investigating the Efficacy and Safety of Grazax in Children Aged 5-16 Years With Grass Pollen Induced Rhinoconjunctivitis With or Without Asthma
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 253 (actual)
- Sponsor
- ALK-Abelló A/S · Industry
- Sex
- All
- Age
- 5 Years – 16 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to investigate if immunotherapy with Grazax is safe and reduces the hayfever symptoms and the use of symptom relieving medications in children during the grass pollen season
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Grazax-R | Grass tablet, 75.000 SQ per day for one year |
| BIOLOGICAL | Grazax Placebo | Grazax Placebo, 0 SQ tablet per day for one year |
Timeline
- Start date
- 2006-11-01
- Primary completion
- 2007-09-01
- Completion
- 2007-11-01
- First posted
- 2006-12-07
- Last updated
- 2009-03-09
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT00408616. Inclusion in this directory is not an endorsement.